# Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia

> **NCT01769274** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 5 (actual)

## Conditions studied

- Inherited Erythromelalgia

## Interventions

- **DRUG:** PF-05089771
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01769274
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-22
- **Primary completion:** 2013-07-12
- **Final completion:** 2013-07-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769274, "Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01769274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*